Enveric Biosciences

Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB)
A New Approach to Solving Mental Health Challenges.

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Leveraging its unique discovery and development platform, The Psybrary™, Enveric has created a robust Intellectual Property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of anxiety disorders. Enveric is also advancing its second program, the EVM301 Series, to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.

01/30/2026

Enveric CEO Joseph Tucker, PhD, comments on the Company’s recently announced expanded collaboration with TOTEC Pharma through its trademark license and option. For more information, visit: https://bit.ly/4qHBVhy

Enveric's trademark license to TOTEC includes an option to purchase the RCANN trademark portfolio in the future, conting...
01/29/2026

Enveric's trademark license to TOTEC includes an option to purchase the RCANN trademark portfolio in the future, contingent on TOTEC meeting certain development and commercialization milestones. Read more: https://bit.ly/4qHBVhy

Enveric has announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. its US Trademark portfol...
01/29/2026

Enveric has announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology, is advancing the commercialization of patented cannabinoid crème technology created by Enveric and intended for use in treatment of radiation dermatitis. https://bit.ly/4qHBVhy

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules...
01/28/2026

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules https://bit.ly/49MWtPL

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules https://bi...
01/28/2026

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules https://bit.ly/4t45LhR

Neuroplastogens are becoming one of the most important areas in neuropsychiatric drug development. Microdose details Env...
01/23/2026

Neuroplastogens are becoming one of the most important areas in neuropsychiatric drug development. Microdose details Enveric’s strong neuroplastogen patent coverage and the development of its lead candidate, EB-003, designed to deliver the rapid and durable benefits associated with psychedelics while avoiding hallucinations. Read it here: https://bit.ly/4pOytAp

Enveric’s first-in-class neuroplastogen, EB-003, has the potential to redefine the treatment landscape for mental health...
01/22/2026

Enveric’s first-in-class neuroplastogen, EB-003, has the potential to redefine the treatment landscape for mental health disorders. With low side effects, strong efficacy, and potential synergy with current drugs, demand is expected to grow as the neuroplastogen market is projected to reach $35.4B by 2030. Find out more: https://bit.ly/4nrEDp9

Current neuropsychiatric treatments often deliver limited efficacy, delayed onset (4–6 weeks), and high dropout rates du...
01/13/2026

Current neuropsychiatric treatments often deliver limited efficacy, delayed onset (4–6 weeks), and high dropout rates due to side effects. Enveric’s non-hallucinogenic neuroplastogen, EB-003, has the potential to transform the treatment paradigm by overcoming the limitations of both approved antidepressants and hallucinogenic neuroplastogens. Learn more about our novel drug: https://bit.ly/3pbHq9W

Join us on January 11th at the Sachs Associates 9th Annual Neuroscience Innovation Forum during J.P. Morgan Week 2026 wh...
01/05/2026

Join us on January 11th at the Sachs Associates 9th Annual Neuroscience Innovation Forum during J.P. Morgan Week 2026 where Enveric will present and participate in the panel discussion "Meeting the Promise of Psychedelics Panel: Expected Trends for 2026". For details: https://bit.ly/4iCNpQl

Enveric’s newly granted U.S. Patent expands protection of its pipeline of potentially neuroplastogenic and non-hallucino...
12/30/2025

Enveric’s newly granted U.S. Patent expands protection of its pipeline of potentially neuroplastogenic and non-hallucinogenic molecules, and strengthens the Company’s ability to target neuropsychiatric, neurological and addiction disorders for patients with few options. Learn more: https://bit.ly/4pl9kgH

12/29/2025

Our CEO, Joseph Tucker, Ph.D., comments on the Company's new U.S. patent which expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions. For more info: https://bit.ly/4pl9kgH

Enveric today announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic ...
12/29/2025

Enveric today announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives”, with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders. For details: https://bit.ly/4pl9kgH

Address

Naples, FL
34103

Website

Alerts

Be the first to know and let us send you an email when Enveric Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Enveric Biosciences:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category